SG11201912267SA - Nicotinamide riboside derivatives and their uses - Google Patents
Nicotinamide riboside derivatives and their usesInfo
- Publication number
- SG11201912267SA SG11201912267SA SG11201912267SA SG11201912267SA SG11201912267SA SG 11201912267S A SG11201912267S A SG 11201912267SA SG 11201912267S A SG11201912267S A SG 11201912267SA SG 11201912267S A SG11201912267S A SG 11201912267SA SG 11201912267S A SG11201912267S A SG 11201912267SA
- Authority
- SG
- Singapore
- Prior art keywords
- nicotinamide riboside
- riboside derivatives
- derivatives
- nicotinamide
- riboside
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/048—Pyridine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762521717P | 2017-06-19 | 2017-06-19 | |
| PCT/US2018/038201 WO2018236814A2 (en) | 2017-06-19 | 2018-06-19 | Nicotinamide riboside derivatives and their uses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201912267SA true SG11201912267SA (en) | 2020-01-30 |
Family
ID=62875307
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201912267SA SG11201912267SA (en) | 2017-06-19 | 2018-06-19 | Nicotinamide riboside derivatives and their uses |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US11286274B2 (en) |
| EP (1) | EP3642214A2 (en) |
| SG (1) | SG11201912267SA (en) |
| WO (1) | WO2018236814A2 (en) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200138921A1 (en) * | 2017-06-23 | 2020-05-07 | The Trustees Of Columbia University In The City Of New York | Methods of preventing and treating diseases characterized by synaptic dysfunction and neurodegeneration including alzheimer's disease |
| WO2019089417A1 (en) * | 2017-10-30 | 2019-05-09 | Elysium Health, Inc. | Methods and compositions for treating cystic fibrosis |
| US20200384004A1 (en) * | 2017-12-01 | 2020-12-10 | Elysium Health, Inc. | Methods and compositions for treating glaucoma |
| CN108841781A (en) * | 2018-06-13 | 2018-11-20 | 延边大学 | Crocin is improving the application in porcine oocytes oxidation resistance and cleavage rates |
| US11833167B2 (en) | 2018-12-17 | 2023-12-05 | Mitopower Llc | Nicotinyl riboside compounds and their uses |
| US11266696B2 (en) * | 2019-01-18 | 2022-03-08 | Americord Registry Llc | Method of treating stem cells with NAD |
| CN109674808A (en) * | 2019-01-30 | 2019-04-26 | 四川大学 | β-nicotinamide mononucleotide or its precursor are preparing the purposes delayed in lung senescence drug |
| WO2020191359A1 (en) * | 2019-03-21 | 2020-09-24 | Fred Hutchinson Cancer Research Center | Cancer combination therapies utilizing a nicotinamide phosphoribosyltransferase inhibitor in combination with a nicotinamide adenine dinucleotide salvage pathway precursor |
| WO2020190703A1 (en) * | 2019-03-21 | 2020-09-24 | Elysium Health, Inc. | Methods for wound treatment |
| CA3141641A1 (en) * | 2019-06-05 | 2020-12-10 | Societe Des Produits Nestle S.A. | Reduced nicotinamideribosides for treating/preventing skeletal muscle disease |
| US20220296623A1 (en) * | 2019-06-05 | 2022-09-22 | Societe Des Produits Nestle S.A. | Reduced nicotinamideribosides for treating or preventing kidney disease |
| EP3980027A1 (en) * | 2019-06-05 | 2022-04-13 | Société des Produits Nestlé S.A. | Reduced nicotinamideribosides for the treatment/prevention of liver disease |
| EP3986420A1 (en) * | 2019-06-18 | 2022-04-27 | Mitopower LLC | Nicotinyl riboside compounds and their uses |
| WO2021021668A1 (en) * | 2019-07-26 | 2021-02-04 | Allegro Pharmaceuticals, LLC | Peptides for treating non-exudative macular degeneration and other disorders of the eye |
| FR3102058A1 (en) * | 2019-10-18 | 2021-04-23 | Nuvamid Sa | Use of NMN for the prevention and / or treatment of rheumatoid arthritis and corresponding compositions |
| JP2022554277A (en) * | 2019-10-30 | 2022-12-28 | パフューズ セラピューティクス， インコーポレイテッド | Treatment of eye disease using endothelin receptor antagonists |
| WO2021098725A1 (en) * | 2019-11-19 | 2021-05-27 | Tsinghua University | Synthetic method for nmn derivative and medical applications of nmn and its derivative |
| CN115103842A (en) | 2020-02-06 | 2022-09-23 | 珀弗斯治疗股份有限公司 | Compositions for treating ocular diseases |
| KR20220151628A (en) * | 2020-03-06 | 2022-11-15 | 알레그로 파마슈티칼스, 엘엘씨 | Treatment to improve or reduce impairment of mitochondrial function |
| CN115066246A (en) * | 2020-03-09 | 2022-09-16 | 雀巢产品有限公司 | Compositions and methods comprising reduced nicotinamide riboside for the prevention and treatment of viral and bacterial infections |
| WO2021180741A1 (en) * | 2020-03-09 | 2021-09-16 | Société des Produits Nestlé S.A. | Compositions and methods containing reduced nicotinamide riboside for prevention and treatment of pancreatic diseases and conditions |
| FR3108502B1 (en) * | 2020-03-27 | 2022-09-23 | Nuvamid Sa | NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES IN THE TREATMENT AND PREVENTION OF BACTERIAL INFECTIONS |
| CN111454311B (en) * | 2020-04-03 | 2021-10-19 | 深圳市迪克曼科技开发有限公司 | Organic acid salt of nicotinamide ribose, composition and preparation method thereof |
| US20210353656A1 (en) * | 2020-05-12 | 2021-11-18 | Nuvamid Sa | Combination of nicotinamide mononucleotide derivatives and histamine h2 receptor antagonists for viral infections |
| EP3949964A1 (en) * | 2020-08-06 | 2022-02-09 | Nuvamid SA | Combination of nicotinamide mononucleotide derivatives and other therapeutic agents for use in the treatment of viral infections |
| WO2022029275A1 (en) * | 2020-08-06 | 2022-02-10 | Nuvamid Sa | Combination of nicotinamide mononucleotide derivatives and other therapeutic agents for use in the treatment of coronavirus infections and covid-19 |
| CN112500445B (en) * | 2020-12-04 | 2022-11-29 | 黄冈鲁班药业股份有限公司 | Preparation method of beta-nicotinamide ribose |
| CN113274363B (en) * | 2021-04-29 | 2023-02-10 | 珠海润都制药股份有限公司 | Indapamide preparation |
| EP4329753A1 (en) | 2021-04-30 | 2024-03-06 | Perfuse Therapeutics, Inc. | Pharmaceutical compositions and intravitreal drug delivery systems for the treatment of ocular diseases |
| WO2022266322A1 (en) * | 2021-06-18 | 2022-12-22 | Mitopower Llc | Treatment of immune-related disorders, kidney disorders, liver disorders, hemolytic disorders, and oxidative stress-associated disorders using nrh, narh and reduced derivatives thereof |
| WO2022269064A1 (en) * | 2021-06-24 | 2022-12-29 | Vestlandets Innovasjonsselskap As (Vis) | Nad-augmentation therapy for parkinson's disease |
| WO2023102344A1 (en) * | 2021-12-01 | 2023-06-08 | University Of Florida Research Foundation, Incorporated | Combinatorial therapeutic approach for friedreich's ataxia |
| CN115232184A (en) * | 2021-12-06 | 2022-10-25 | 宁波熙健医药科技有限公司 | Ribofuranosyl pyridine derivative, and pharmaceutical composition and use thereof |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1190079A (en) | 1966-07-29 | 1970-04-29 | Kyowa Hakko Kogyo Company Ltd | Process for producing Nicotinamide Adenine Dinucleotide |
| US6589948B1 (en) | 2000-11-28 | 2003-07-08 | Eukarion, Inc. | Cyclic salen-metal compounds: reactive oxygen species scavengers useful as antioxidants in the treatment and prevention of diseases |
| CA2530407A1 (en) | 2003-07-23 | 2005-02-03 | The Regents Of The University Of California | Penetration enhancer combinations for transdermal delivery |
| CA2555675A1 (en) | 2004-02-10 | 2005-08-25 | Trustees Of Dartmouth College | Nicotinamide riboside kinase compositions and methods for using the same |
| EP1877054A2 (en) | 2005-03-30 | 2008-01-16 | Sirtris Pharmaceuticals, Inc. | Nicotinamide riboside and analogues thereof |
| US20070099830A1 (en) * | 2005-04-21 | 2007-05-03 | Massachusetts Institute Of Technology | Sirt4 activities |
| US20130216542A1 (en) | 2005-05-06 | 2013-08-22 | Zymogenetics, Inc. | Variable region sequences of il-31 monoclonal antibodies and methods of use |
| EP3369738B1 (en) * | 2005-11-18 | 2020-05-20 | Cornell Research Foundation, Inc. | Method for making nicotinoyl ribosides and nicotinamide beta-riboside |
| AU2009240747A1 (en) | 2008-04-22 | 2009-10-29 | Merck Frosst Canada Ltd | Novel substituted heteroaromatic compounds as inhibitors of stearoyl-coenzyme A delta-9 desaturase |
| US20110306597A1 (en) | 2008-06-18 | 2011-12-15 | James Michael Crawforth | Nicotinamide Derivatives |
| US20140065099A1 (en) * | 2011-02-15 | 2014-03-06 | Ecole Polytechnique Federale De Lausanne (Epfl) | Methods of Treating Mitochondrial Dysfunction |
| AU2014236687A1 (en) | 2013-03-15 | 2015-09-10 | Nusirt Sciences, Inc. | Leucine and nicotinic acid reduces lipid levels |
| GB201313465D0 (en) | 2013-07-29 | 2013-09-11 | Queens University Of The Belfast | Methods of preparing nicotinamide riboside and derivatives thereof |
| KR20220098049A (en) | 2013-10-30 | 2022-07-08 | 크로마덱스 아이엔씨. | Nicotinamide riboside compositions for topical use in treating skin conditions |
| US10316054B2 (en) | 2014-06-02 | 2019-06-11 | Glaxosmithkline Intellectual Property (No. 2) Limited | Preparation and use of crystalline beta-D-nicotinamide riboside |
| MX2016016071A (en) | 2014-06-06 | 2017-07-11 | Glaxosmithkline Intellectual Property (No 2) Ltd | Nicotinamide riboside analogs and pharmaceutical compositions and uses thereof. |
| CA2956163C (en) | 2014-07-24 | 2023-01-10 | W.R. Grace & Co.-Conn. | Crystalline form of nicotinamide riboside |
| WO2016122832A1 (en) | 2015-01-30 | 2016-08-04 | Natural Formulations | Compositions, therapeutic and prophylactic methods for treatment of neurodegenerative diseases and brain injuries |
| KR102629310B1 (en) | 2015-03-09 | 2024-01-24 | 더블유.알. 그레이스 앤드 캄파니-콘. | Crystal form of nicotinamide riboside |
| KR102426320B1 (en) | 2015-03-16 | 2022-07-29 | 크로마덱스 아이엔씨. | Nicotinic acid riboside or nicotinamide riboside compositions, reduced derivatives thereof, and uses thereof |
| WO2016196941A1 (en) | 2015-06-04 | 2016-12-08 | Chromadex, Inc. | Selective solvent free phosphorylation |
| EP3322419A4 (en) | 2015-07-15 | 2018-08-01 | Cornell University | Syntheses, activities, and methods of use of dihydronicotinamide riboside derivatives |
| WO2017024255A1 (en) | 2015-08-05 | 2017-02-09 | Metrobiotech, Llc | Nicotinamide mononucleotide derivatives and their uses |
| IL299824B2 (en) | 2015-10-07 | 2024-02-01 | Huizenga Joel | Resetting biological pathways for defending against and repairing deterioration from human aging |
| WO2017079195A1 (en) * | 2015-11-02 | 2017-05-11 | Mitobridge, Inc. | Nicotinamide riboside and nicotinamide mononucleotide derivatives for use in the treatments of mitochondrial-related diseases |
| AU2016375177B2 (en) | 2015-12-24 | 2022-09-01 | Amazentis Sa | Compositions comprising nicotinamide riboside and a urolithin |
| WO2017161165A1 (en) | 2016-03-16 | 2017-09-21 | ChromaDex Inc. | B-vitamin and amino acid conjugates of nicotinoyl ribosides and reduced nicotinoyl ribosides, derivatives thereof, and methods of preparation thereof |
| EP3442527A4 (en) | 2016-04-14 | 2019-12-18 | Chromadex Inc. | Use of nicotinamide riboside, nicotinic acid riboside, nicotinamide mononucleotide, and nicotinoyl compound derivatives in infant formula |
| NZ747693A (en) | 2016-04-20 | 2023-07-28 | Chromadex Inc | Use of nicotinic acid riboside or nicotinamide riboside derivatives, and reduced derivatives thereof, as nad+increasing precursors |
| WO2017218580A1 (en) | 2016-06-14 | 2017-12-21 | Rejuvenation Therapeutics Corporation | Synthetic methods for the preparation of nicotinamide riboside and related compounds |
| WO2018002215A1 (en) | 2016-06-30 | 2018-01-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of cardiomyopathies |
| GB2553001A (en) | 2016-08-19 | 2018-02-21 | The Queen's Univ Of Belfast | Lactone intermediates of nicotinamide riboside and nicotinate riboside |
| BR112019003579A2 (en) | 2016-08-22 | 2019-05-21 | Elysium Health Inc | COMPOSITIONS OF NICOTINAMIDE AND PTEROSTYLENE RIBOSIDE AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS |
| US9975915B1 (en) | 2016-11-11 | 2018-05-22 | The Queen's University Of Belfast | Crystalline forms of nicotinoyl ribosides, modified derivatives thereof, and phosphorylated analogs thereof, and methods of preparation thereof |
| US11071747B2 (en) * | 2016-11-29 | 2021-07-27 | University Of Iowa Research Foundation | Use of NAD precursors for breast enhancement |
| EP3554285A4 (en) * | 2016-11-29 | 2021-01-20 | University of Iowa Research Foundation | Use of nad precursors for improving maternal health and/or offspring health |
| ES2924710T3 (en) | 2017-03-17 | 2022-10-10 | Elysium Health Inc | Nicotinamide riboside for use in treating or preventing liver damage |
-
2018
- 2018-06-19 SG SG11201912267SA patent/SG11201912267SA/en unknown
- 2018-06-19 WO PCT/US2018/038201 patent/WO2018236814A2/en unknown
- 2018-06-19 US US16/012,004 patent/US11286274B2/en active Active
- 2018-06-19 EP EP18740009.8A patent/EP3642214A2/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018236814A3 (en) | 2019-02-07 |
| US20180362570A1 (en) | 2018-12-20 |
| EP3642214A2 (en) | 2020-04-29 |
| US11286274B2 (en) | 2022-03-29 |
| WO2018236814A2 (en) | 2018-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201912267SA (en) | Nicotinamide riboside derivatives and their uses | |
| ZA201801196B (en) | Nicotinamide mononucleotide derivatives and their uses | |
| ZA201808131B (en) | Amide-substituted pyridinyltriazole derivatives and uses thereof | |
| HK1248240A1 (en) | Nicotinic acid riboside or nicotinamide riboside compositions, reduced derivatives thereof, and the use thereof | |
| HK1254654A1 (en) | 4,6-pyrimidinylene derivatives and uses thereof | |
| IL253656A0 (en) | Substituted mono- and polyazanaphthalene derivatives and their use | |
| EP3268362A4 (en) | Substituted pyridines and uses thereof | |
| HK1250164A1 (en) | Aniline pyrimidine derivatives and uses thereof | |
| HK1246156B (en) | Fgf21 derivatives and uses thereof | |
| IL273839A (en) | Benzimidazole derivatives and their uses | |
| HK1251226A1 (en) | Pyridine and pyrimidine derivatives | |
| EP3526215A4 (en) | N-acylethanolamide derivatives and uses thereof | |
| RS62819B1 (en) | Aminopyridine derivatives and their use as selective alk-2 inhibitors | |
| SG11202008543RA (en) | Pyrrolidineamide derivatives and uses thereof | |
| EP3383401A4 (en) | Thieno-pyrimidine derivatives and uses thereof | |
| GB2577419B (en) | Lipo-glycopeptide cleavable derivatives and uses thereof | |
| IL274722A (en) | Pyridinone derivatives and their use as selective alk-2 inhibitors | |
| EP3556764A4 (en) | Nucleoside derivative and use therefor | |
| EP3712160A4 (en) | Nucleoside derivative and use thereof |